Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor - PubMed (original) (raw)

Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor

D Vercammen et al. J Exp Med. 1998.

Abstract

Murine L929 fibrosarcoma cells treated with tumor necrosis factor (TNF) rapidly die in a necrotic way, due to excessive formation of reactive oxygen intermediates. We investigated the role of caspases in the necrotic cell death pathway. When the cytokine response modifier A (CrmA), a serpin-like caspase inhibitor of viral origin, was stably overexpressed in L929 cells, the latter became 1,000-fold more sensitive to TNF-mediated cell death. In addition, TNF sensitization was also observed when the cells were pretreated with Ac-YVAD-cmk or zDEVD-fmk, which inhibits caspase-1- and caspase-3-like proteases, respectively. zVAD-fmk and zD-fmk, two broad-spectrum inhibitors of caspases, also rendered the cells more sensitive, since the half-maximal dose for TNF-mediated necrosis decreased by a factor of 1,000. The presence of zVAD-fmk also resulted in a more rapid increase of TNF-mediated production of oxygen radicals. zVAD-fmk-dependent sensitization of TNF cytotoxicity could be completely inhibited by the oxygen radical scavenger butylated hydroxyanisole. These results indicate an involvement of caspases in protection against TNF-induced formation of oxygen radicals and necrosis.

PubMed Disclaimer

Figures

Figure 1

Figure 1

CrmA expression enhances TNF-induced necrosis. (A) Western blot analysis of transfected L929 clones. Lane 1, control L929 cells transfected with pSV2neo alone; lanes 2–4, different clones cotransfected with pCAGGS CrmA and pSV2neo. Arrowhead, CrmA expression. (B) Sensitizing effect on TNF-mediated necrosis in L929 cells. ▿, control; •, clone 2; ○, clone 5; and ▾, clone 12.

Figure 1

Figure 1

CrmA expression enhances TNF-induced necrosis. (A) Western blot analysis of transfected L929 clones. Lane 1, control L929 cells transfected with pSV2neo alone; lanes 2–4, different clones cotransfected with pCAGGS CrmA and pSV2neo. Arrowhead, CrmA expression. (B) Sensitizing effect on TNF-mediated necrosis in L929 cells. ▿, control; •, clone 2; ○, clone 5; and ▾, clone 12.

Figure 2

Figure 2

Sensitizing effect of peptide caspase inhibitors on TNF-induced necrosis in L929 cells, added 2 h before TNF treatment. (A) Without addition of BHA. •, Ac-YVAD-cmk (100 μM); ○, zDEVD-fmk (100 μM); ▾, Ac-YVAD-cmk + zDEVD-fmk (100 μM each); ▿, zVAD-fmk (25 μM); ▪, zD-fmk (25 μM); □, zAAD-cmk (100 μM); and ♦, control. (B) With BHA (100 μM) added at the same time as TNF (same symbols as in A).

Figure 2

Figure 2

Sensitizing effect of peptide caspase inhibitors on TNF-induced necrosis in L929 cells, added 2 h before TNF treatment. (A) Without addition of BHA. •, Ac-YVAD-cmk (100 μM); ○, zDEVD-fmk (100 μM); ▾, Ac-YVAD-cmk + zDEVD-fmk (100 μM each); ▿, zVAD-fmk (25 μM); ▪, zD-fmk (25 μM); □, zAAD-cmk (100 μM); and ♦, control. (B) With BHA (100 μM) added at the same time as TNF (same symbols as in A).

Figure 3

Figure 3

Effect of zVAD-fmk on TNF-induced reactive oxygen formation and cell death. (A) Effect on TNF-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, TNF alone (500 IU/ml); ○, TNF + BHA (100 μM); ▾, TNF + zVAD-fmk (25 μM); ▿, TNF + zVAD-fmk + BHA; and ▪, zVAD-fmk alone. (B) Effect on TNF-induced cell killing determined on the basis of PI-negative cells (same experiment and symbols as in A).

Figure 3

Figure 3

Effect of zVAD-fmk on TNF-induced reactive oxygen formation and cell death. (A) Effect on TNF-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, TNF alone (500 IU/ml); ○, TNF + BHA (100 μM); ▾, TNF + zVAD-fmk (25 μM); ▿, TNF + zVAD-fmk + BHA; and ▪, zVAD-fmk alone. (B) Effect on TNF-induced cell killing determined on the basis of PI-negative cells (same experiment and symbols as in A).

Figure 4

Figure 4

Effect of zVAD-fmk on radical scavenging in L929 cells. (A) zVAD-fmk does not alter free thiol concentrations. Cells were treated with zVAD-fmk (25 μM) for 4 h [zVAD-fmk (-4)] or 2 h [zVAD-fmk (-2)] before TNF addition, or with DEM 3 h after TNF addition. Open bars, without TNF; filled bars, 1,000 IU/ml TNF. (B) Effect of zVAD-fmk on H2O2- or tBuOOH-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, H2O2 (50 μM); ○, H2O2 + zVAD-fmk (25 μM); ▾, tBuOOH (100 μM); ▿, tBuOOH + zVAD-fmk; and ▪, zVAD-fmk alone.

Figure 4

Figure 4

Effect of zVAD-fmk on radical scavenging in L929 cells. (A) zVAD-fmk does not alter free thiol concentrations. Cells were treated with zVAD-fmk (25 μM) for 4 h [zVAD-fmk (-4)] or 2 h [zVAD-fmk (-2)] before TNF addition, or with DEM 3 h after TNF addition. Open bars, without TNF; filled bars, 1,000 IU/ml TNF. (B) Effect of zVAD-fmk on H2O2- or tBuOOH-induced oxygen radical production (relative DHR123 fluorescence as compared to untreated cells). •, H2O2 (50 μM); ○, H2O2 + zVAD-fmk (25 μM); ▾, tBuOOH (100 μM); ▿, tBuOOH + zVAD-fmk; and ▪, zVAD-fmk alone.

Figure 5

Figure 5

Inhibitory effect of zVAD-fmk on TNF-mediated apoptosis in HeLa H21 cells (• and ○; 1 μg/ml actinomycin D added) and KYM cells (▾ and ▿). Open symbols, TNF only; closed symbols, 25 μM zVAD-fmk added 2 h before TNF treatment.

Figure 6

Figure 6

Possible mechanisms of action in caspase inhibitor-mediated sensitization of TNF-induced necrosis in L929 cells. A putative caspase (CASP-X ), inhibited by CrmA or zVAD-fmk, acts as a negative regulator of premitochondrial signaling (1) or mitochondrial production of reactive oxygen intermediates (ROI; 2). Alternatively, damaging of mitochondria by ROI could impair normal functioning, resulting in an even higher radical production; normally, the cell possesses a mechanism to remove these damaged mitochondria by a process involving one or more caspases (3). Interference with this clean-up process enhances necrosis.

References

    1. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452. - PubMed
    1. Fiers, W. 1995. Biologic therapy with TNF: preclinical studies. In Biologic Therapy of Cancer. 2nd ed. V.T. DeVita, Jr., S. Hellman, and S.A. Rosenberg, editors. J.B. Lippincott, Philadelphia. 295–327.
    1. Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Lett. 1997;410:96–106. - PubMed
    1. Grooten J, Goossens V, Vanhaesebroeck B, Fiers W. Cell membrane permeabilization and cellular collapse, followed by loss of dehydrogenase activity: early events in tumour necrosis factor–induced cytotoxicity. Cytokine. 1993;5:546–555. - PubMed
    1. Goossens V, Grooten J, De Vos K, Fiers W. Direct evidence for tumor necrosis factor–induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci USA. 1995;92:8115–8119. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources